Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP624872.RA1dJMg0OB0-J0CXKmRqfgIUhuCaWP3RYGS7wM6XUezUA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP624872.RA1dJMg0OB0-J0CXKmRqfgIUhuCaWP3RYGS7wM6XUezUA130_assertion type Assertion NP624872.RA1dJMg0OB0-J0CXKmRqfgIUhuCaWP3RYGS7wM6XUezUA130_head.
- NP624872.RA1dJMg0OB0-J0CXKmRqfgIUhuCaWP3RYGS7wM6XUezUA130_assertion description "[Class I phosphoinositide 3-kinases (PI3K) have been extensively studied in different models these last years and several isoforms are now promising drug targets to treat cancer and immune diseases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624872.RA1dJMg0OB0-J0CXKmRqfgIUhuCaWP3RYGS7wM6XUezUA130_provenance.
- NP624872.RA1dJMg0OB0-J0CXKmRqfgIUhuCaWP3RYGS7wM6XUezUA130_assertion evidence source_evidence_literature NP624872.RA1dJMg0OB0-J0CXKmRqfgIUhuCaWP3RYGS7wM6XUezUA130_provenance.
- NP624872.RA1dJMg0OB0-J0CXKmRqfgIUhuCaWP3RYGS7wM6XUezUA130_assertion SIO_000772 24095650 NP624872.RA1dJMg0OB0-J0CXKmRqfgIUhuCaWP3RYGS7wM6XUezUA130_provenance.
- NP624872.RA1dJMg0OB0-J0CXKmRqfgIUhuCaWP3RYGS7wM6XUezUA130_assertion wasDerivedFrom befree-20150227 NP624872.RA1dJMg0OB0-J0CXKmRqfgIUhuCaWP3RYGS7wM6XUezUA130_provenance.
- NP624872.RA1dJMg0OB0-J0CXKmRqfgIUhuCaWP3RYGS7wM6XUezUA130_assertion wasGeneratedBy ECO_0000203 NP624872.RA1dJMg0OB0-J0CXKmRqfgIUhuCaWP3RYGS7wM6XUezUA130_provenance.